Log in  First Connection?
  
EnglishJapaneseFrenchSpanishGerman

Blood CancerArchives

Sexual health and intimacy concerns among patients with chronic lymphocytic leukemia: a cross-sectional needs assessment study
Blood Cancer
 1 min.

 Published on 09/06/2026 |  Original article (Full-text)  | Ilana Levy Yurkovski et al. | Leukemia & Lymphoma 2026; aop:10.1080/10428194.2026.2682282

Sexual health is an important component of survivorship, yet data specific to chronic lymphocytic leukemia (CLL) are limited. We aimed to characterize self-reported sexual health concerns and supportive care needs among adults with CLL. In this cross-sectional anonymous survey, adults with CLL completed...

HTML version PDF version  Print abstract

Plasma proteome profiles of standard-risk and high-risk childhood acute lymphoblastic leukemia
Blood Cancer
 1 min.

 Published on 02/06/2026 |  Original article (Full-text)  | Najia Tabassum et al. | Expert Review of Proteomics 2026; aop:10.1080/14789450.2026.2676596

This exploratory study aimed to characterize plasma proteome profiles across different risk groups and investigate underlying molecular mechanisms using bioinformatics approaches. This is a case-control study. Plasma samples from 15 children per group- standard-risk B-ALL (B-ALL SR), high-risk B-ALL...

HTML version PDF version  Print abstract

Real-world venetoclax dosing patterns and treatment persistence in patients with acute myeloid leukemia: a community pharmacy database study in Japan
Blood Cancer
 1 min.

 Published on 26/05/2026 |  Original article (Full-text)  | Yuki Goshima a b et al. | Leukemia & Lymphoma 2026; aop:10.1080/10428194.2026.2665793

Venetoclax (VEN)-based regimens are widely used for patients with acute myeloid leukemia (AML) who are ineligible for intensive chemotherapy, but VEN dosing patterns and their relation to treatment persistence are not well described. We conducted a retrospective longitudinal study using de-identified...

HTML version PDF version  Print abstract

Long non-coding RNAs and survival outcomes in chronic lymphocytic leukemia
Blood Cancer
 1 min.

 Published on 19/05/2026 |  Original article (Full-text)  | Teodora Karan-Djurasevic et al. | Pharmacogenomics 2026; 27(3-4): 159-177

Chronic lymphocytic leukemia (CLL) is a highly heterogeneous hematological malignancy characterized by pronounced differences in clinical course and genetic . While research has historically focused on alterations in protein-coding genes, it is increasingly evident that the non-coding transcriptome plays...

HTML version PDF version  Print abstract

Combined asciminib and olverembatinib in blast-phase chronic myeloid leukemia
Blood Cancer
 1 min.

 Published on 12/05/2026 |  Original article (Full-text)  | Fang Cheng et al. | Haematologica. Volume 111(4).

Chronic myeloid leukemia (CML) is a clonal myeloproliferative disorder typically managed with BCR::ABL1 tyrosine kinase inhibitors (TKI). However, it can progress from chronic phase (CML-CP) to blast phase (CML-BP), during which BCR::ABL1 kinase domain (KD) genetic variants (e.g., T315I, Y253H) and aberrant...

HTML version PDF version  Print abstract